Last reviewed · How we verify

NCT06674369

Ongoing Effect of Expansion Prisms Following the Discontinuation of Use on Visual Field Enlargement and Retrograde Ganglion Cell Degeneration in Homonymous Hemianopia Patients

Active, enrolled Last updated 5 November 2024
What this trial tests

trial testing Peli prism for hemianopia in Homonymous Hemianopsia in 15 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
28 August 2022
Primary endpoint
18 October 2022
30 October 2024

Quick facts

Lead sponsorOkan University
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment15
Start date28 August 2022
Primary completion18 October 2022
Estimated completion30 October 2024
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Okan University

Who can join

Adults 18 Months to 55 Months, any sex, with Homonymous Hemianopsia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to learn about the long-term effects of Pelli prism in Hemianopia patients who take Prisms for awareness of the area they cannot see. The main question it aims to answer is: Does the field enlargement observed with the prism continues after the prism is removed? Participants already using Peli prisms as part of their regular medical care for Hemianopia, in the upcoming routine controls their field of vision enlargements will be examined.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Homonymous Hemianopsia

Currently open trials in the same condition.

Other Okan University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06674369.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing